ASH 2025 | Epcoritamab monotherapy before chemoimmunotherapy in Richter’s transformation: Epcore CLL-1

So what we show in two back-to-back abstracts today in the session on rare lymphomas including Richter’s transformation is that I will first talk about the longer-term outcome of epcoritamab monotherapy. Richter’s transformation is this disease, a complication of CLL with very, very bad prognosis. No standard therapy actually is really successful, and median overall survival is less than one year, with actually mostly chemoimmunotherapy. And what we have showed and earlier presented at ASH very preliminary was that if you now come as a bispecific antibody-binding CD3 on one side and CD20 on the other side, that we saw premature efficacy in patients. And now we have more patients in the study, longer follow-up. And what we now see is that specifically in patients that are treated with epcoritamab at first line, so before they got any chemotherapy, of course, they had before CLL and therapies for that one. But after the Richter’s transformation, first treatment, they did very, very well, actually, with a longer… If patients have a remission, it really seems to be sustained. So the PFS has not yet reached. And we saw a median overall survival of 27 months. If you give the therapy, however, after chemoimmunotherapy, there are still patients that respond, but it’s vastly less well and less efficacious. You might use it for bridging therapy, but I think if you consider this kind of treatment in the future, then giving it prior to chemotherapy, so first treatment probably will be the best way to go.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.